MedTrace Logo

Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone

NCT02098746 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 294

Last updated 2016-10-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term use of pioglitazone/glimepiride combination tablets (Sonias Combination Tablets LD) in patients with type 2 diabetes mellitus who respond poorly to pioglitazone hydrochloride monotherapy (pioglitazone at 15 mg/day) in the routine clinical setting.

Conditions

Interventions

DRUG

Pioglitazone/glimepiride

Pioglitazone/glimepiride combination tablets

Sponsors & Collaborators

Principal Investigators

  • Postmarketing Group Manager · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-07-31
Completion
2014-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02098746 on ClinicalTrials.gov